Stay updated with breaking news from Clinical Trial Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire™...
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary...
An accurate assessment of a patient's kidney function is critical for determining eligibility for anticancer treatments. In a paper published today in...
Press release content from Business Wire. The AP news staff was not involved in its creation.
ABBVie announced today that the European Commission has approved VENCLYXTO ® in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. 1 The approval is valid in all 27 member states of the EU, as well as Iceland Liechtenstein and Norway . “VENCLYXTO has proven incremental … – ABBVie (NYSE: ABBV) announced today that the European Commission (EC) has approved VENCLYXTO ® (venetoclax) in combination with a hypomethylating agent, azacitidine or d...